FDA Approves New Option in Obesity - Quiz - MDSpire

FDA Approves New Option in Obesity

The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.

  • By

  • Kathryn Wighton

  • February 23, 2026

  • 3 min

Share

Original Source(s)

FDA Approves New Option in Obesity

  • by Kathryn Wighton

  • February 23, 2026

Related Content

An epidemiological assessment of the distribution and sociodemographic burden of chronic diseases: a focus on hypertension, diabetes, and cardiovascular conditions

Opposing gastric and jejunal regulation of CELA2A in obesity and after Roux-en-Y gastric bypass suggests a role in gastrointestinal metabolic signaling

Editorial: Cardiovascular Anthropometry For Large Scale Population Studies Volume II